{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:32:03Z","timestamp":1784367123687,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T12:52:48Z","timestamp":1613047968000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognosis and risk stratification of peripheral T-cell lymphomas"],"prefix":"10.1053","volume":"58","author":[{"given":"Mary-Kate","family":"Malecek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2021.02.001_bib0001","first-page":"717","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Annals of oncology: official journal of the European Society for","volume":"9","author":"Anderson","year":"1998","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0003","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of peripheral T-cell lymphoma diagnostic workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0007","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0008","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0009","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0011","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0012","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0014","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0015","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0016","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0017","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.25450","article-title":"Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma","volume":"94","author":"Maura","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0019","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ncomms2260","article-title":"T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements","volume":"3","author":"Kanhere","year":"2012","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0021","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma\u2013NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0022","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/10428190701784409","article-title":"Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas","volume":"49","author":"Sch\u00fctzinger","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0023","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0024","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0025","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0026","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International Peripheral T-Cell Lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0028","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0029","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00277-008-0494-8","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies","volume":"87","author":"Khong","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0031","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/10428190701344915","article-title":"F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas","volume":"48","author":"Bishu","year":"2007","journal-title":"Leukemia Lymphoma"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0032","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0033","unstructured":"National Comprehensive Cancer Network Clinical Guidlines in Oncology: T-cell Lymphomas [11-22-2020]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell_blocks.pdf."},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/RLU.0000000000002320","article-title":"FDG PET for evaluation of bone marrow status in T-cell lymphoma","volume":"44","author":"Koh","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2019-126068","article-title":"Utility and patterns of use of PET\/CT and bone marrow biopsy for staging in non-Hodgkin lymphoma in the clinical setting: a retrospective analysis using the LEO database","volume":"134","author":"Strouse","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0036","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0037","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0038","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0039","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0041","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood advances"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0043","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0044","first-page":"2419","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's","volume":"374","author":"Johnson","year":"2016","journal-title":"Lymphoma"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0046","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0047","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0048","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.V120.21.2721.2721","article-title":"The role of interim-PET and Final-PET in the outcome of peripheral T-Cell Lymphoma (PTCL) treated at the diagnosis with CHOP","volume":"120","author":"Pellegrini","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0049","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: a review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0050","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nuc Med"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0051","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1002\/cam4.3226","article-title":"Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma","volume":"9","author":"Kitadate","year":"2020","journal-title":"Cancer Med"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0052","series-title":"BioMed Res Int","article-title":"Prognostic Values of Baseline (18)F-FDG PET\/CT in patients with peripheral T-cell lymphoma","author":"Zhou","year":"2020"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0053","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","article-title":"Utility of \u00b9\u2078fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Horwitz","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0054","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0055","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0056","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V85.9.2632.bloodjournal8592632","article-title":"Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients","volume":"85","author":"Radich","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0057","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0058","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0059","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0061","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2015.12.018","article-title":"Cutaneous T-cell lymphoma (CTCL): current practices in blood assessment and the utility of T-cell receptor (TCR)-V\u03b2 chain restriction","volume":"74","author":"Gibson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0062","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0063","first-page":"2728","article-title":"Next-generation sequencing based monitoring of circulating-tumor DNA in untreated peripheral T-cell lymphoma","volume":"130","author":"Melani","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0064","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0065","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00277-017-3038-2","article-title":"Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma","volume":"96","author":"Sakata-Yanagimoto","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0066","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/bloodadvances.2019001075","article-title":"Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma","volume":"4","author":"Ottolini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0067","series-title":"T-cell Lymphoma Forum; January 26-28","article-title":"Peripheral blood cell free DNA can identiy tumor specific somatic mutations in angioimmunoblastic T-cell lymphoma","author":"Mehta-Shah","year":"2017"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0068","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-138768","article-title":"End of treatment peripheral blood T-cell receptor gene rearrangement evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas","volume":"136","author":"Mehta-Shah","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0069","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bjh.16447","article-title":"The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma","volume":"189","author":"Hong","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0070","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1080\/10428194.2019.1602266","article-title":"The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma","volume":"60","author":"Sun","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0071","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/annonc\/mdv486","article-title":"Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2R\u03b1 as predictors of event-free survival in T-cell lymphoma","volume":"27","author":"Gupta","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0072","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0073","doi-asserted-by":"crossref","unstructured":"Lee J, Suh C, Park YH, et\u00a0al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. 2006;24:612-18.","DOI":"10.1200\/JCO.2005.04.1384"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0074","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0075","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0076","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0077","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","article-title":"Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project","volume":"7","author":"Fox","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0078","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/RLU.0000000000002440","article-title":"18F-FDG PET\/CT for prognostic stratification of patients with extranodal natural killer\/T-cell lymphoma","volume":"44","author":"Qin","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0079","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134665","volume":"136","author":"Gao","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.001_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The Echelon-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:27:48Z","timestamp":1758522468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000111"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis and risk stratification of peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}